AUS
NZ
UK
CA
USA
IND
Highlights
- Arch Biopartners expands Phase II trial of LSALT peptide for CS-AKI, adding Royal Columbian Hospital in B.C.
- Patient enrollment continues at Canadian sites, with additional locations in Canada and the U.S. under evaluation.
- Arch completes acquisition of Lipdro Therapeutics, issuing 250,000 shares and securing royalties on CKD drugs.
- Board grants 750,000 stock options to directors and officers, exercisable at CAD 1.70 per share for 10 years.
Arch Biopartners Inc. (TSX Venture:ARCH) (OTCQB:ACHFF) is advancing on multiple fronts, announcing several key developments. The company is expanding its Phase II clinical trial for the LSALT peptide in cardiac surgery-associated acute kidney injury (CS-AKI), with ongoing patient enrollment at Canadian sites.
In addition, Arch has completed its acquisition of Lipdro Therapeutics Inc. and granted stock options to its directors and officers, further strengthening its corporate and leadership framework.
Arch Biopartners is a therapeutic biotech company, is focused on developing novel treatments for acute and chronic kidney diseases. The pipeline includes:
Data source: Company update
Phase II CS-AKI Clinical Trial Expansion
The company has announced approval from the Fraser Health Research Ethics Board (REB) for Royal Columbian Hospital (RCH) in British Columbia to join its Phase II clinical trial of the LSALT peptide, aimed at preventing and treating CS-AKI.
Following this approval, the clinical team at RCH in British Columbia will complete operational approvals, staff training, and site initiation before beginning patient enrollment. Once activated, RCH will become the eighth site globally and the fourth in Canada to enroll patients.
Ongoing Patient Enrollment and Site Expansion
Patient enrollment continues at other Canadian sites, with Arch also actively evaluating additional sites in both Canada and the U.S. to further expand the CS-AKI trial.
Data source: Company update
Corporate Updates: Lipdro Acquisition and Stock Options
The company has received final approval from the TSX Venture Exchange for its acquisition of Lipdro Therapeutics Inc. The deal was first announced on September 17, 2025, and involved Arch issuing 250,000 common shares and agreeing to a royalty on future net sales of certain chronic kidney disease (CKD) drugs from the acquired platform targeting IL-32.
The company's board has also granted 750,000 stock options to directors and officers. These options, which are part of the company's stock option plan, are exercisable at CAD 1.70 per share for a period of ten years starting on November 4, 2025. The options, subject to regulatory approvals, are intended to compensate the board members for their service.
ARCH shares traded at CAD 1.06 per share on November 5, 2025.
